31
January 2024
Eden Research
Plc
("Eden" or
"Company")
Board Change
Eden Research plc (AIM: EDEN), the
AIM-quoted company focused on sustainable biopesticides and
plastic-free formulation technology for use in the global crop
protection, animal health and consumer products industries,
announces that Richard Horsman has stepped down as non-executive
director with immediate effect.
Lykele van der Broek, Non-executive Chairman,
commented:
"I would like to thank Richard for his
contributions and insights over the past 18 months, which was a
pivotal time for the Company during which we made a great deal of
progress. The Board is grateful for Richard's input and has
benefitted from his experience. We wish Richard well in all of his
many endeavours".
For further
information contact:
Eden Research
plc
www.edenresearch.com
Sean Smith
01285 359 555
Alex Abrey
Cavendish
Capital Markets Limited (Nominated advisor and
broker)
Giles Balleny / George Lawson (corporate
finance)
020 7397 8900
Michael Johnson (sales)
Hawthorn
Advisors (Financial PR)
eden@hawthornadvisors.com
Victoria Ainsworth
Notes to Editors:
Eden Research is the only UK-listed company
focused on biopesticides for sustainable agriculture. It develops
and supplies innovative biopesticide products and natural
microencapsulation technologies to the global crop protection,
animal health and consumer products industries.
Eden's products are formulated with terpene
active ingredients, based on natural plant defence metabolites. To
date, they have been primarily used on high-value fruits and
vegetables, improving crop yields and marketability, with equal or
better performance when compared with conventional pesticides. Eden
has three products currently on the market:
Based on plant-derived active ingredients,
Mevalone® is a foliar biofungicide which initially targets a key
disease affecting grapes and other high-value fruit and vegetable
crops. It is a useful tool in crop defence programmes and is
aligned with the requirements of integrated pest management
programmes. It is approved for sale in a number of key countries
whilst Eden and its partners pursue regulatory clearance in new
territories thereby growing Eden's addressable market
globally.
Cedroz™ is a bionematicide that targets free
living nematodes which are parasitic worms that affect a wide range
of high-value fruit and vegetable crops globally. Cedroz is
registered for sale on two continents and Eden's commercial
collaborator, Eastman Chemical, is pursuing registration and
commercialisation of this important new product in numerous
countries globally.
Eden's seed treatment product, Ecovelex was
developed to safely tackle crop destruction caused by birds - a
major cause of losses in maize and other crops. Ecovelex works by
creating an unpleasant taste or odour that repels birds, leaving
the seeds safely intact and the birds unaffected and free to find
alternative food sources. The product is based on Eden's
plant-derived chemistry, registered in the EU, U.S. and elsewhere,
and formulated using Eden's Sustaine® microencapsulation
system.
Eden's Sustaine® encapsulation technology is
used to harness the biocidal efficacy of naturally occurring
chemicals produced by plants (terpenes) and can also be used with
both natural and synthetic compounds to enhance their performance
and ease-of-use. Sustaine microcapsules are naturally-derived,
plastic-free, biodegradable micro-spheres derived from yeast. It is
one of the only viable, proven and immediately registerable
solutions to the microplastics problem in formulations requiring
encapsulation.
Eden was admitted to trading on AIM on 11 May
2012 and trades under the symbol EDEN. It was awarded the London
Stock Exchange Green Economy Mark in January 2021, which recognises
London-listed companies that derive over 50% of their total annual
revenue from products and services that contribute to the global
green economy. Eden derives 100% of its total annual revenues from
sustainable products and services.
For more information about Eden, please visit:
www.edenresearch.com. You can also follow Eden's latest
developments via its social media channels: X (Twitter) and
LinkedIn.